Briacell Therapeutics -CW27BCTXWPreferred / convertible
13F holders, Q1 2025 (March 31)7holders +3
3new positions
0sold out
$0.10avg. 13F price*
At the end of Q1 2025, 7 institutions reported holding Briacell Therapeutics -CW27 (BCTXW) in their 13F filings, up 3 from Q4 2024. 3 opened new positions and 0 sold out. The largest holders were Redmond Asset Management, LLC ($8K), Two Sigma Securities, LLC ($3K) and Armistice Capital, LLC ($3K).
- Company
- Briacell Therapeutics -CW27
- CUSIP
- 10778Y112
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $5K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 47,184 shares bought and 353,724 shares sold, net −306,540 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Redmond Asset Management, LLC | — | No change | 75,000 | $8K |
| Two Sigma Securities, LLC | — | New | 30,838 | $3K |
| Armistice Capital, LLC | — | Reduce -93.3% | 25,000 | $3K |
| Susquehanna International Group, LLP | — | New | 16,246 | $1K |
| UBS Group AG | — | Reduce -58.1% | 2,689 | $274 |
| Osaic Holdings, Inc. | — | No change | 800 | $72 |
| Clear Street LLC | — | New | 100 | $10 |
"% of holder's portfolio" is BCTXW's weight in each manager's 13F, not the share of Briacell Therapeutics -CW27 the manager owns.